Literature DB >> 27523272

Acute Reverse Remodelling After Transcatheter Aortic Valve Implantation: A Link Between Myocardial Fibrosis and Left Ventricular Mass Regression.

Laura Elizabeth Dobson1, Tarique A Musa1, Akhlaque Uddin1, Timothy A Fairbairn1, Peter P Swoboda1, Bara Erhayiem1, James Foley1, Pankaj Garg1, Philip Haaf1, Graham J Fent1, Christopher J Malkin2, Daniel J Blackman2, Sven Plein1, John P Greenwood3.   

Abstract

BACKGROUND: Despite the wealth of data showing the positive effects on cardiac reverse remodelling in the long-term, the immediate effects of transcatheter aortic valve implantation (TAVI) on the left ventricle are yet to be comprehensively described using cardiovascular magnetic resonance imaging. Also, the link between myocardial fibrosis and acute left ventricular (LV) mass regression is unknown.
METHODS: Fifty-seven patients with severe aortic stenosis awaiting TAVI underwent paired cardiovascular magnetic resonance scans before and early after the procedure (4 [interquartile range, 3-5] days). LV mass, volume, and function were measured. Late gadolinium enhancement (LGE) imaging was performed to assess for the presence of and pattern of myocardial fibrosis.
RESULTS: After the procedure, 53 (95%) patients experienced an immediate (10.1 ± 7.1%) reduction in indexed LV mass (LVMi) from 76 ± 15.5 to 68.4 ± 14.7 g/m2 (P < 0.001). Those with no LGE experienced the greatest LVMi regression (13.9 ± 7.1%) compared with those with a midwall/focal fibrosis pattern LGE (7.4 ± 5.8%) and infarct pattern LGE (7.2 ± 7.0%; P = 0.005). There was no overall change in LV ejection fraction (LVEF; 55.1 ± 12.1% to 55.5 ± 10.9%; P = 0.867), however a significant improvement in LVEF was seen in those with abnormal (< 55%; n = 24; 42%) baseline LVEF (43.2 ± 8.9 to 46.7 ± 10.5%; P = 0.027). Baseline LVMi (P = 0.005) and myocardial fibrosis (P < 0.001) were strong independent predictors of early LVMi regression.
CONCLUSIONS: LV reverse remodelling occurs immediately after TAVI, with significant LV mass regression in the total population and an improvement in LVEF in those with preexisting LV impairment. Those without myocardial fibrosis at baseline experience greater LV mass regression than those with fibrosis. Copyright Â
© 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27523272     DOI: 10.1016/j.cjca.2016.04.009

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  9 in total

1.  Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction.

Authors:  Pankaj Garg; Hosamadin Assadi; Rachel Jones; Wei Bin Chan; Peter Metherall; Richard Thomas; Rob van der Geest; Andrew J Swift; Abdallah Al-Mohammad
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 2.  Valvular Heart Disease in Women, Differential Remodeling, and Response to New Therapies.

Authors:  Jaya Chandrasekhar; George Dangas; Roxana Mehran
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-09-11

3.  Cardiac structural changes after transcatheter aortic valve replacement: systematic review and meta-analysis of cardiovascular magnetic resonance studies.

Authors:  Ghazaleh Mehdipoor; Shmuel Chen; Saurav Chatterjee; Pooya Torkian; Ori Ben-Yehuda; Martin B Leon; Gregg W Stone; Martin R Prince
Journal:  J Cardiovasc Magn Reson       Date:  2020-06-01       Impact factor: 5.364

4.  Acute haemodynamic impact of transcatheter aortic valve implantation in patients with severe aortic stenosis.

Authors:  Francesca Graziani; Pio Cialdella; Rosa Lillo; Gabriella Locorotondo; Lorenzo Genuardi; Gessica Ingrasciotta; Stefano Cangemi; Marialisa Nesta; Piergiorgio Bruno; Cristina Aurigemma; Enrico Romagnoli; Michele Calabrese; Nicole Giambusso; Antonella Lombardo; Francesco Burzotta; Carlo Trani
Journal:  ESC Heart Fail       Date:  2022-03-29

5.  The Predictive Value of Left Atrial Strain Following Transcatheter Aortic Valve Implantation on Anatomical and Functional Reverse Remodeling in a Multi-Modality Study.

Authors:  Borbála Vattay; Anikó Ilona Nagy; Astrid Apor; Márton Kolossváry; Aristomenis Manouras; Milán Vecsey-Nagy; Levente Molnár; Melinda Boussoussou; Andrea Bartykowszki; Ádám L Jermendy; Tímea Kováts; Emese Zsarnóczay; Pál Maurovich-Horvat; Béla Merkely; Bálint Szilveszter
Journal:  Front Cardiovasc Med       Date:  2022-04-25

6.  Functional and structural reverse myocardial remodeling following transcatheter aortic valve replacement: a prospective cardiovascular magnetic resonance study.

Authors:  Torben Lange; Sören J Backhaus; Bo Eric Beuthner; Rodi Topci; Karl-Rudolf Rigorth; Johannes T Kowallick; Ruben Evertz; Moritz Schnelle; Susana Ravassa; Javier Díez; Karl Toischer; Tim Seidler; Miriam Puls; Gerd Hasenfuß; Andreas Schuster
Journal:  J Cardiovasc Magn Reson       Date:  2022-07-28       Impact factor: 6.903

7.  Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis.

Authors:  Miriam Puls; Bo Eric Beuthner; Rodi Topci; Anja Vogelgesang; Annalen Bleckmann; Maren Sitte; Torben Lange; Sören Jan Backhaus; Andreas Schuster; Tim Seidler; Ingo Kutschka; Karl Toischer; Elisabeth Maria Zeisberg; Claudius Jacobshagen; Gerd Hasenfuß
Journal:  Eur Heart J       Date:  2020-05-21       Impact factor: 29.983

8.  Prognostic value of pre-procedural left ventricular strain for clinical events after transcatheter aortic valve implantation.

Authors:  Noriko Suzuki-Eguchi; Mitsushige Murata; Yuji Itabashi; Kousuke Shirakawa; Memori Fukuda; Jin Endo; Hikaru Tsuruta; Takahide Arai; Kentaro Hayashida; Hideyuki Shimizu; Keiichi Fukuda
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

Review 9.  Futility in Transcatheter Aortic Valve Implantation: A Search for Clarity.

Authors:  Kush P Patel; Thomas A Treibel; Paul R Scully; Michael Fertleman; Samuel Searle; Daniel Davis; James C Moon; Michael J Mullen
Journal:  Interv Cardiol       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.